841 related articles for article (PubMed ID: 24183799)
1. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
[TBL] [Abstract][Full Text] [Related]
2. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen.
Mills JP; Wilck MB; Weikert BC; Porrett PM; Timko D; Alby K; Bonomo RA; Blumberg EA
Transpl Infect Dis; 2016 Oct; 18(5):777-781. PubMed ID: 27458980
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
[TBL] [Abstract][Full Text] [Related]
6. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
7. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.
Falagas ME; Rafailidis PI; Matthaiou DK; Virtzili S; Nikita D; Michalopoulos A
Int J Antimicrob Agents; 2008 Nov; 32(5):450-4. PubMed ID: 18768302
[TBL] [Abstract][Full Text] [Related]
8. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
Falcone M; Russo A; Iacovelli A; Restuccia G; Ceccarelli G; Giordano A; Farcomeni A; Morelli A; Venditti M
Clin Microbiol Infect; 2016 May; 22(5):444-50. PubMed ID: 26850826
[TBL] [Abstract][Full Text] [Related]
9. Emergence of concurrent infections with colistin-resistant ESBL-positive Klebsiella pneumoniae and OXA-23-producing Acinetobacter baumannii sensitive to colistin only in a Romanian cardiac intensive care unit.
Timofte D; Dan M; Maciuca IE; Ciucu L; Dabija ER; Guguianu E; Panzaru CV
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):2069-74. PubMed ID: 26239064
[TBL] [Abstract][Full Text] [Related]
10. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients.
Mastoraki A; Douka E; Kriaras I; Stravopodis G; Manoli H; Geroulanos S
Surg Infect (Larchmt); 2008 Apr; 9(2):153-60. PubMed ID: 18426347
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
13. Over-treatment of carbapenemase-producing Enterobacteriaceae.
Rihani DS; Wallace MR; Sieger BE; Waite RA; Fox M; Brown SA; Deryke CA
Scand J Infect Dis; 2012 May; 44(5):325-9. PubMed ID: 22200121
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
Evren E; Azap OK; Çolakoğlu Ş; Arslan H
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
Karaiskos I; Giamarellou H
Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095
[TBL] [Abstract][Full Text] [Related]
16. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge.
Navarro-San Francisco C; Mora-Rillo M; Romero-Gómez MP; Moreno-Ramos F; Rico-Nieto A; Ruiz-Carrascoso G; Gómez-Gil R; Arribas-López JR; Mingorance J; Paño-Pardo JR
Clin Microbiol Infect; 2013 Feb; 19(2):E72-9. PubMed ID: 23231088
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
18. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series.
Falagas ME; Siempos II; Rafailidis PI; Korbila IP; Ioannidou E; Michalopoulos A
Respir Med; 2009 May; 103(5):707-13. PubMed ID: 19118994
[TBL] [Abstract][Full Text] [Related]
19. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
[TBL] [Abstract][Full Text] [Related]
20. Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.
Papadimitriou-Olivgeris M; Bartzavali C; Spyropoulou A; Lambropoulou A; Sioulas N; Vamvakopoulou S; Karpetas G; Spiliopoulou I; Vrettos T; Anastassiou ED; Fligou F; Christofidou M; Marangos M
Diagn Microbiol Infect Dis; 2018 Nov; 92(3):235-240. PubMed ID: 30076041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
